Factory 99% Nintedanib Esylate Powder CAS 656247-18-6 Chemical Intermediate

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A898
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Nintedanib Esylate
• CAS: 656247-18-6
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Nintedanib Esylate
Appearance	White Powder
CAS NO.	656247-18-6
Storage	Keep in a cool, dry, dark location

 

Nintedanib Esylate, also known as BIBF 1120 esylate, is a small molecule tyrosine kinase inhibitor (TKI) that exhibits both antifibrotic and anti-inflammatory activities. It is primarily used in the treatment of idiopathic pulmonary fibrosis (IPF).

 

1. Treatment of Idiopathic Pulmonary Fibrosis (IPF): Nintedanib Esylate is approved for the treatment of IPF, a chronic and progressive lung disease characterized by scarring of the lungs. It helps to slow down the progression of the disease and improve patients' quality of life.
2. Research and Development: Due to its inhibitory effects on multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs), Nintedanib Esylate is also used in research settings to investigate its potential in treating other fibrotic conditions and cancer.
3. Combination Therapy: It is often used in combination with other medications to enhance its therapeutic effects and reduce the risk of adverse reactions.

1. Inhibition of RTKs and nRTKs: Nintedanib Esylate selectively inhibits multiple RTKs, including receptor (PDGFR), fibroblast receptor (FGFR), and receptor (VEGFR), as well as nRTKs such as Lck, Lyn, and Src kinases. This inhibition disrupts the signaling pathways involved in fibrosis and inflammation.
2. Antifibrotic Activity: By inhibiting the proliferation, migration, and differentiation of fibroblasts, Nintedanib Esylate reduces the formation of collagen and other extracellular matrix components, thereby the fibrotic process in the lungs.
3. Anti-inflammatory Activity: Additionally, Nintedanib Esylate exhibits anti-inflammatory properties by modulating the immune response and reducing the production of inflammatory cytokines and chemokines.